Compare VVOS & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | XAIR |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 3.0M |
| IPO Year | 2020 | 2015 |
| Metric | VVOS | XAIR |
|---|---|---|
| Price | $0.09 | $2.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.93 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.6M | 20.4K |
| Earning Date | 11-23-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,443,000.00 | $7,679,000.00 |
| Revenue This Year | $24.92 | $4.23 |
| Revenue Next Year | $56.44 | $108.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 16.05 | ★ 107.26 |
| 52 Week Low | $0.09 | $0.33 |
| 52 Week High | $2.69 | $8.19 |
| Indicator | VVOS | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 22.35 | 52.19 |
| Support Level | N/A | $2.38 |
| Resistance Level | $0.36 | $3.30 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 4.91 | 73.33 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.